Phase I trial of volasertib (BI 6727), a polo-like kinase 1 (Plk1) inhibitor, in combination with cisplatin or carboplatin in patients with advanced solid tumors.
Year: 2011
Type: conference-abstract
Abstract: 3031 Background: Volasertib (V) is a potent and highly selective inhibitor of Plk1, a key regulator of cell-cycle progression. Preclinical data showed that V and Cisplatin (Cis) or carboplatin (Ca) combination may confer additional benefit. Methods: Sequential cohorts of 3 to 6 patients (pts) received a single 2-hour infusion of V in combination with Cis (arm A) or Ca (arm B), on day 1 every 3 weeks. Cis and Ca were given for up to 6 cycles (Cy), V was continued until disease progression or unacceptable toxicity. Maximum tolerated dose (MTD) is defined as the highest dose at which ≥1 pt out of a maximum (max) of 6 experienced Dose Limiting Toxicity (DLT) during Cy 1. Results: As of January 14, 2011, 36 pts (18 each arm) were treated. Pt characteristics were (arm A/B): median age 52/57.5 years, male 39/72%, ECOG PS 0: 44/39%, PS 1: 50/61%. Tumors were: NSCLC (22%), sarcoma (14%), colorectal cancer (11%), melanoma (11%), other (42%). Pts received the combination therapy for a median [range] of 4 Cy [1-6] in arm A and 2 Cy [2-6] in arm B and V for a max of 15 and 11 Cy in arms A and B respectively. Only 2 DLTs (Cy 1) were observed, 1 in arm A at DL A5 (grade 4 CTC version 3 neutropenia for >7 days) and 1 in arm B at DL B4 (grade 4 thrombocytopenia). The most frequent drug related grade 3 or 4 AEs by pt were (% of pts arm A/B): anemia 6/6, neutropenia 33/33, thrombocytopenia 6/22, febrile neutropenia 6/0, vomiting 6/0, fatigue 11/6. Grade 1/2 QTc prolongation was observed in 2 pts (DL A2, B4). MTD in both arms has not yet been reached at predefined DLs. Three partial responses were seen: 2 in pts with CHOP-resistant follicular dendritic reticulum cell sarcoma in arm A (DL A2, A4) and 1 pt with heavily-pretreated head and neck carcinoma in arm B (DL B4). Stable disease was reported in 50% and 39% of pts in arm A and B respectively, and 5 and 3 pts had long stabilization (> 6 Cy). Conclusions: V in combination with Cis or Ca is well tolerated and demonstrates preliminary evidence of antitumor activity. Extension cohorts at DLs A5 and B5 are ongoing to confirm the recommended doses. Dose levels (DL) Arm A: Cis (mg/m2)/n of pts Arm B: Ca (AUC)/n of pts V (mg) A1/B1 60/3 4/3 100 A2/B2 75/3 5/3 100 A3/B3 75/3 5/3 200 A4/B4 75/3 5/6 300 A5/B5 100/6 6/3 300
Source: Journal of Clinical Oncology
Language: English
Subfield: Cell Biology
Domain: Life Sciences
Open Access status: green
OpenAlex ID: W823948869
